Houston hospital named among smartest in the nation

hi, tech

The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
From Your Site Articles
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

The home of the Rice Owls is on top once again. Photo via Rice University

Rice University named top college in U.S. News' new rankings for 2025

top of class

Houston's own "Ivy League of the South" has come out on top as one of the best universities in the nation for 2025, according to U.S. News and World Report's just-released list of the Best Colleges for 2025.

Rice University claimed No. 1 in Texas, and ranked No. 18 nationally in a one-spot slip from last year's ranking. The private institution has a 98 percent first-year retention rate, and an "actual" graduation rate of 96 percent. Rice costs $60,709 in tuition and fees for students each year, and according to the school's profile, it has an acceptance rate of eight percent.

In April, Rice's Jesse H. Jones Graduate School of Business ranked No. 2 in U.S. News' ranking of the best graduate schools in Texas, with its entrepreneurship program tying for No. 8 nationally, and the part-time MBA program ranking No. 15 overall. Those rankings may change in the next few years once the school finishes its brand new facility for the business school.

Rice also fared similarly in Niche'slist of best colleges, in which it ranked No. 15 nationally. Forbes ranked the university No. 9 nationwide in its list of best colleges for the 2024-2025 school year, and Rice was bestowed an "Ivy League" status in Forbes' recent report on top public and private schools that churn out top graduates.

“We are delighted to see Rice University recognized as one of America’s producers of great talent. Rice has been a recruiting destination for employers for many years and that is because Rice students are adaptable, curious, bright, and are solution oriented,” Nicole Van Den Heuvel, executive director of the Center for Career Development, says in a news release from Rice.

In a glowing review of the university, one former business student said studying at Rice was a "transformative experience."

"Rice is the perfect blend of rigorous academics, strong athletics, and a nurturing and engaging social life," the reviewer wrote. "It's quite idyllic. Rice is known as a STEM school, but it has distinguished programs in humanities, social sciences, music and architecture too. Professors are top scholars in their fields and will know you by name. Students are well prepared academically, but are also collaborative and supportive."

Right behind Rice in the rankings is The University of Texas at Austin, which ranked No. 2 in Texas and No. 30 nationally. Just behind UT Austin is College Station's Texas A&M University, which placed No. 3 in the Texas rankings and No. 51 nationally.

The University of Houston maintained its No. 8 rank in the statewide comparison, but fell 11 spots down into No. 144 in the national rankings.

The University of St. Thomas ranked No. 9 in Texas, and moved up seven places to rank No. 209 in the U.S. for 2025.

U.S. News' top 10 best colleges in Texas in 2024 are:

  • No. 1 – Rice University, Houston
  • No. 2 – University of Texas at Austin
  • No. 3 – Texas A&M University, College Station
  • No. 4 – Baylor University, Waco
  • No. 5 – Southern Methodist University, Dallas
  • No. 6 – Texas Christian University, Fort Worth
  • No. 7 – The University of Texas at Dallas, Richardson
  • No. 8 – University of Houston
  • No. 9 – University of St. Thomas, Houston
  • No. 10 – Texas Tech University, Lubbock

The full rankings can be found on usnews.com.

------

This article originally ran on CultureMap.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

MD Anderson Cancer Center is still the best cancer-focused hospital in the U.S. and Texas. Photo by F. Carter Smith/courtesy of MD Anderson

Houston hospitals recognized as best in state, nation in annual report

better than all the rest

Houston’s University of Texas MD Anderson Cancer Center has retained its U.S. News & World Report crown as the best cancer hospital in the U.S.

In the same ranking, Houston Methodist Hospital once again came out on top as the best hospital in Texas. Last year, the hospital shared the top spot. Baylor St. Luke’s Medical Center ranked No. 4, followed by No. 5 Memorial Hermann Hospital.

The accolades appear in U.S. News’ 2024-25 ranking of the country’s best hospitals. Each hospital also ranked among various specialties, such as orthopedics; cardiology, heart, and vascular surgery; cancer; and neurology and neurosurgery.

Since U.S. News introduced its annual hospital survey in 1990, MD Anderson has been ranked one of the two best U.S. hospitals for cancer care. It has maintained its No. 1 ranking for 10 consecutive years.

“At MD Anderson, our mission is clear: to end cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “This ranking reflects our relentless commitment to excellence in patient care, research, prevention, and education.”

MD Anderson also ranked highly in three specialties:

  • No. 2 for ear, nose, and throat.
  • No. 9 for urology.
  • No. 14 for gastroenterology and GI surgery.

“The consistent top national recognitions [that] MD Anderson receives for delivering compassionate, evidence-based care is a testament to our dedication to those we serve,” Pisters says.

Elsewhere at the Texas Medical Center, Houston Methodist Hospital was named the No. 1 hospital in Texas for the 13th year in a row. Also, it was lauded as one of the country’s 20 best hospitals for the eighth time.

Along with the general ranking, Houston Methodist Hospital scored high marks in 10 specialties. These include diabetes and endocrinology (No. 6), gastroenterology and GI surgery (No. 7), and pulmonology and lung surgery (No. 8).

Meanwhile, four Houston Methodist community hospitals ranked well in Texas:

  • Houston Methodist The Woodlands Hospital (No. 8).
  • Houston Methodist Sugar Land Hospital (No. 9).
  • Houston Methodist Baytown Hospital (tied at No. 18).
  • Houston Methodist Willowbrook Hospital (tied at No. 23).
The University of Houston — along with a couple of other Houston-area schools — made the cut of the top 100 schools for U.S. patents granted. Photo courtesy of UH.edu

Houston-area schools score spots on of annual list of top universities for patents issued

new report

The University of Houston System reigns as the patent king among colleges and universities in the Houston area.

A new list from the National Academy of Inventors puts UH in a 63rd-place tie — with 27 utility patents issued in 2023 — among 100 recognized schools. As the university explains, utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights to produce and use their technology.

Other schools in the Houston area that show up on the list are the Texas A&M University System, tied for 30th place with 66 patents, and Rice University, tied for 93rd place with 14 patents.

The University of Rochester in New York shares the No. 63 spot with UH.

“This ranking highlights the commitment of our faculty researchers, who explore frontiers of knowledge to enhance the well-being of our society,” Ramanan Krishnamoorti, vice president of energy and innovation at UH, says in a news release. “At UH, we are committed to creating new technologies that drive innovation, to boost Houston’s economy and tackle some of the most perplexing problems facing us.”

Among the UH discoveries that received utility patents last year are:

  • Methods of targeting cancer stem cells
  • Materials, systems, and methods for carbon capture and conversion.
  • A medical device that positions and tracks the muscular activity of legs.

Elsewhere in Texas:

  • University of Texas System, holding the No. 3 spot with 235 patents
  • Texas Tech University System, tied for 74th place with 20 patents
  • Baylor University, tied for 80th place with 17 patents
  • University of North Texas, tied for 90th place with 15 patents

Ahead of the UT System on the list are the University of California (546 patents) and the Massachusetts Institute of Technology (365 patents).

“As we look at the current and future state of innovation in our nation, we need to ensure that the U.S. is remaining competitive in the international innovation ecosystem,” Paul Sanberg, president of the National Academy of Inventors, says in a news release. “Protecting intellectual property is a key component to this, and the … list allows us to recognize and celebrate universities and their faculty, staff, and students who are not only innovating at high levels but taking the additional step of protecting their IP through patenting.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston VC funding surged in 2024, fueled by major Q4 activity

by the numbers

The venture capital haul for Houston-area startups jumped 23 percent from 2023 to 2024, according to the latest PitchBook-NVCA Venture Monitor.

The fundraising total for startups in the region climbed from $1.49 billion in 2023 to $1.83 billion in 2024, PitchBook-NVCA Venture Monitor data shows.

Roughly half of the 2024 sum, $914.3 million, came in the fourth quarter. By comparison, Houston-area startups collected $291.3 million in VC during the fourth quarter of 2023.

Among the Houston-area startups contributing to the impressive VC total in the fourth quarter of 2024 was geothermal energy startup Fervo Energy. PitchBook attributes $634 million in fourth-quarter VC to Fervo, with fulfillment services company Cart.com at $50 million, and chemical manufacturing platform Mstack and superconducting wire manufacturer MetOx International at $40 million each.

Across the country, VC deals total $209 billion in 2024, compared with $162.2 billion in 2023. Nearly half (46 percent) of all VC funding in North America last year went to AI startups, PitchBook says. PitchBook’s lead VC analyst for the U.S., Kyle Stanford, says that AI “continues to be the story of the market.”

PitchBook forecasts a “moderately positive” 2025 for venture capital in the U.S.

“That does not mean that challenges are gone. Flat and down rounds will likely continue at higher paces than the market is accustomed to. More companies will likely shut down or fall out of the venture funding cycle,” says PitchBook. “However, both of those expectations are holdovers from 2021.”

Justice Department sues to block Houston-based HPE's $14B buyout of Juniper

M&A News

The Justice Department sued to block Hewlett Packard Enterprise's $14 billion acquisition of rival Juniper Networks on Thursday, the first attempt to stop a merger by a new Trump administration that is expected to take a softer approach to mergers.

The Justice complaint alleges that Hewlett Packer Enterprise, under increased competitive pressure from the fast-rising Juniper, was forced to discount products and services and invest more in its own innovation, eventually leading the company to simply buy its rival.

The lawsuit said that the combination of businesses would eliminate competition, raise prices and reduce innovation.

HPE and Juniper issued a joint statement Thursday, saying the companies strongly oppose the DOJ's decision.

“We will vigorously defend against the Department of Justice’s overreaching interpretation of antitrust laws and will demonstrate how this transaction will provide customers with greater innovation and choice, positively change the dynamics in the networking market,” the companies said.

The combined company would create more competition, not less, the companies said.

The Justice Department's intervention — the first of the new administration and just 10 days after Donald Trump's inauguration — comes as somewhat of a surprise. Most predicted a second Trump administration to ease up on antitrust enforcement and be more receptive to mergers and deal-making after years of hypervigilance under former President Joe Biden’s watch.

Hewlett Packard Enterprise announced one year ago that it was buying Juniper Networks for $40 a share in a deal expected to double HPE’s networking business.

In its complaint, the government painted a picture of Hewlett Packard Enterprise as a company desperate to keep up with a smaller rival that was taking its business.

HPE salespeople were concerned about the “Juniper threat,” the complaint said, also alleging that one former executive told his team that “there are no rules in a street fight,” encouraging them to “kill” Juniper when competing for sales opportunities.

The Justice Department said that Hewlett Packard Enterprise and Juniper are the U.S.'s second- and third-largest providers of wireless local area network (WLAN) products and services for businesses.

“The proposed transaction between HPE and Juniper, if allowed to proceed, would further consolidate an already highly concentrated market — and leave U.S. enterprises facing two companies commanding over 70% of the market,” the complaint said, adding that Cisco Systems was the industry leader.

Many businesses and investors accused Biden regulatory agencies of antitrust overreach and were looking forward to a friendlier Trump administration.

Under Biden, the Federal Trade Commission sued to block a $24.6 billion merger between Kroger and Albertsons that would have been the largest grocery store merger in U.S. history. Two judges agreed with the FTC’s case, blocking the proposed deal in December.

In 2023, the Department of Justice, through the courts, forced American and JetBlue airlines to abandon their partnership in the northeast U.S., saying it would reduce competition and eventually cost consumers hundreds of millions of dollars a year. That partnership had the blessing of the Trump administration when it took effect in early 2021.

U.S. regulators also proposed last year to break up Google for maintaining an “abusive monopoly” through its market-dominate search engine, Chrome. Court hearings on Google’s punishment are scheduled to begin in April, with the judge aiming to issue a final decision before Labor Day. It’s unclear where the Trump administration stands on the case.

One merger that both Trump and Biden agreed shouldn’t go through is Nippon Steel’s proposed acquisition of U.S. Steel. Biden blocked the nearly $15 billion acquisition just before his term ended. The companies challenged that decision in a federal lawsuit early this year.

Trump has consistently voiced opposition to the deal, questioning why U.S. Steel would sell itself to a foreign company given the regime of new tariffs he has vowed.

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

View All Listings